Direct-acting antiviral drugs (DAAs) to treat hepatitis C have proven to be a spectacular success, being able to cure more than 95% of people who have been living with the virus. However, a growing issue has implications for the design of future DAAs, and that is the ability of the hepatitis C virus–like all viruses–to mutate. Mutant versions of viruses can “learn” to defeat the medications used to treat them by changing their structure or the way they interact with the bodies they infect.
When they help the virus evade the effects of medication, we call these changes “drug resistance mutations” (DRMs), and they can make it much harder to cure infections. When a drug-resistant version of a virus becomes the dominant one, it can make a previously useful drug completely ineffective.
Continue reading “Hepatitis C Drug Resistance”
Maureen Cook went from worrying about how long she had to live to planning for a whole new life. It only took her 23 years.
“I found out I had hepatitis C in 2000 when a diligent and insightful GP decided to test me for it when she found out I had hepatitis B back in 1975. I’d cleared the hep B then and didn’t think about it anymore. Didn’t know I had hepatitis C,” she recalled.
Continue reading “Waking to a New Life”
Hep Can’t Wait is the international campaign launched by the World Hepatitis Alliance in 2021. Its aim is to highlight the social injustice and inequity caused by the current lack of action on hepatitis elimination, and focus on the positive action needed to meet the world’s 2030 hepatitis elimination goals.
Continue reading “Asia-Pacific Consensus”